50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2263% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2462% match
“Our mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1562% match
“Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-08-0461% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0861% match
“Our mission is to ensure families are supported during the most difficult time of their lives.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2361% match
“We exist to attack cancer and improve care so people can live longer, more fulfilling lives and have built a team to support innovative oncology drug development.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1860% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0160% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2860% match
“Our mission is to deliver advanced therapies to improve the lives of patients and families battling autoimmune and inflammatory diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-04-1560% match
“Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2560% match
“Our mission is to improve the lives of patients suffering from CNS diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0260% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1660% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1959% match
“Our mission is to bring innovative gene therapy products to patients living with serious, life-threatening rare diseases, and we believe our product candidates have the potential to provide long-lasting and transformative benefits to the patient communities we aim to serve.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0159% match
“Our mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0759% match
“Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-10-0759% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1259% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2959% match
“Our mission is to increase access to care and expand fertility treatment and patient care across the globe.”In use 2021 – now·1 sighting·SEC Form 10-K/A, filed 2021-07-0859% match
“Our mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2459% match
“Our mission is to develop treatments for serious diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2259% match
“Our mission is to overcome the limitations of cytokine therapies and checkpoint inhibitors, such as anti-CTLA-4, and make immunotherapies beyond anti-PD-1/PD-L1 treatments more accessible, efficacious and safe for patients with cancer.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-0159% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0258% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2458% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0758% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3158% match
“Our purpose is to deliver therapies for significant unmet, or under-met, needs to patients, while creating value for our investors.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-1658% match
“Our mission is to make a difference in time for underserved lung cancer patients.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-04-1758% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0758% match
“Our mission is to expand the treatment options for patients who suffer from A fib or have a high risk of stroke through the continued development of our technologies and expansion of our product offerings, global commercial expansion and clinical science investments.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-02-2858% match
“Our mission is to advance the care of patients suffering from life threatening diseases worldwide.”In use 2011 – now·1 sighting·SEC Form 10-K, filed 2011-02-2858% match
“Our mission is to bring life-changing therapeutics to people living with rare diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1258% match
“Our mission is to bring to market therapies that address high unmet medical needs of patients with genetic mitochondrial diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2758% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0158% match
“Our mission is to improve outcomes for patients living with cancer and genetically defined conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0258% match
“Our mission is to enable financial success by changing the way individuals and families plan and achieve their goals through tax-advantaged solutions.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2858% match
“Our mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through our subsidiary MiNK Therapeutics, Inc. (“MiNK”)), and vaccine adjuvants (through our subsidiary SaponiQx, Inc. (“SaponiQx”)).”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1458% match
“Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2358% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1058% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2558% match
“Our mission is to develop and commercialize safe and effective therapies that extend survival and maintain the quality of life for patients with life-threatening cancers and chronic liver diseases.”In use 2004 – now·1 sighting·SEC Form 10-K, filed 2004-12-1358% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2958% match
“Our mission is to improve the lives of patients who suffer from rare diseases for which there are limited or no available treatments, with an initial therapeutic focus on Cirrhosis ascites, patients suffering from AIDS, Cancer and chronic pain, nausea and discomfort associated with chemotherapy and neuropathy.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-11-0658% match
“Our mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.”In use 2015 – now·1 sighting·SEC Form S-1, filed 2015-07-2458% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1158% match
“Strata’s mission is to increase the number of organs that are successfully transplanted while leveraging the Company’s expertise and resources to provide other medical and logistics services to a broader customer base.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0357% match
“Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2757% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1857% match
“Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2857% match
Showing 1–50 of 50